-
Mashup Score: 0Annals of Oncology - 3 year(s) ago
Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides rapid and…
Source: www.journals.elsevier.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Prognostic value of MRD and circulating plasma cells in myeloma - 3 year(s) ago
Jesús San Miguel, MD, Universidad de Navarra, Navarra, Spain, discusses the importance of circulating plasma cells and measurable residual disease…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We caught up with Jesus San Miguel (@ClinicaNavarra) after #ASH20 on the prognostic value of MRD and circulating plasma cells in #Myeloma Check out the video here: 👉https://t.co/VuGH0n5YpB👈 @ASH_hematology #HemOnc #MultipleMyeloma #MMSM #mmMRD #cactc
-
-
Mashup Score: 1
PURPOSE Recent advances in molecular diagnostic technologies have allowed for the evaluation of solid tumor malignancies via noninvasive blood sampling, including circulating tumor DNA (ctDNA) profiling. We sought to characterize the ctDNA genomic alteration landscape in patients with biliary tract cancers (BTCs). PATIENTS AND METHODS From January 2015 to February 2018, 124 patients with BTC at…
Source: JCO Precision OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers [Mar 18, 2019] Mody et al. JCOPO @ASCO_pubs https://t.co/EwnPz17fnF #cactc #hpbcsm #PrecisionMedicine n=124
-
-
Mashup Score: 0
With the promise and potential of clinical next-generation sequencing for tumor and germline testing to impact treatment and outcomes of patients with cancer, there are also risks of oversimplification, misinterpretation, and missed opportunities. These issues risk limiting clinical benefit and, at worst, perpetuating false conclusions that could lead to inappropriate…
Source: JNCCNCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Complexities of Next-Generation Sequencing in Solid #Tumors: Case Studies: https://t.co/zDeEmMvNkH @sokolova_md @Molecular_MD @lobo_goulart @ColinCPritchard @heatherhcheng #camoldx #cagenome #cactc https://t.co/BPXUyJpwNS
-
-
Mashup Score: 0Circulating Tumor Cells In Advanced Cervical Cancer:NRG Oncology - Gynecologic Oncology Group Study 240 (NCT 00803062) - 4 year(s) ago
Purpose: To isolate circulating tumor cells (CTCs) from women with advanced cervical cancer and estimate the impact of CTCs and treatment on overall survival (OS) and progression-free survival (PFS). Experimental Design: 7.5 mL of whole blood was drawn pre-cycle 1 and 36 days post-cycle 1 from patients enrolled on Gynecologic Oncology Group 0240, the phase III randomized trial that led directly…
Source: Molecular Cancer TherapeuticsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Analysis of CTCs in pts with cervical cancer enrolled in the phase III Gynecologic Oncology Group 0240 trial reveals that only those with pre-treatment CTC counts above the median derived PFS and OS benefits from bevacizumab: https://t.co/lzzWHaYOUG #cactc #GynCSM
-
-
Mashup Score: 1Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019 - 4 year(s) ago
Background: Clinical adoption of the sequencing of circulating tumor DNA (ctDNA) for cancer has rapidly increased in recent years. This sequencing is used to select targeted therapy and monitor nonresponding or progressive tumors to identify mechanisms of therapeutic resistance. Our study objective was to review available coverage policies for cancer…
Source: JNCCNCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Private Payer and #MedicareCoverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019: https://t.co/vGNFgV1vLf @MDouglas_MS @StacyWGray @22Kathryn11 #hpeonc #cactc https://t.co/VkfAyOH65I
-
-
Mashup Score: 2SABCS 2017: Circulating Tumor Cells May Predict Late Recurrence in Patients With Hormone Receptor–Positive Breast Cancer - The ASCO Post - 4 year(s) ago
Among 546 patients enrolled, 4.8% had a positive CTC assay result; among patients with hormone receptor–positive breast cancer, 5.1% had a positive CTC result; among those with hormone receptor–negative disease, 4.3% had a positive CTC result. After a median follow-up of 1.6 years, a positive CTC assay result was associated with a nearly 20-fold increased…
Source: www.ascopost.comCategories: Hem/Oncs, Latest HeadlinesTweet-
SABCS 2017: Circulating Tumor Cells May Predict Late Recurrence in Patients With Hormone Receptor–Positive Breast Cancer [12/8/17] @ASCOPost https://t.co/1A14bpi1Qg #bcsm #caprev #cactc
-
-
Mashup Score: 1
PURPOSE Recent advances in molecular diagnostic technologies have allowed for the evaluation of solid tumor malignancies via noninvasive blood sampling, including circulating tumor DNA (ctDNA) profiling. We sought to characterize the ctDNA genomic alteration landscape in patients with biliary tract cancers (BTCs). PATIENTS AND METHODS From January 2015 to February 2018, 124 patients with BTC at…
Source: JCO Precision OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers [Mar 18, 2019] Mody et al. JCOPO @ASCO_pubs https://t.co/EwnPz0PDZ5 #cactc #hpbcsm #PrecisionMedicine n=124
-
-
Mashup Score: 0Circulating giant tumor-macrophage fusion cells are independent prognosticators in non-small cell lung cancer patients - 4 year(s) ago
Various subtypes of circulating cancer-associated cells in the blood are described. A unique circulating, large and polymorphonuclear cell with a dual epithelial and myeloid phenotype has been suggested to be a tumor-macrophage fusion cell (TMF). The goal of the study was to identify the impact of distinct TMFs on survival in non-small cell lung cancer (NSCLC) patients.
Source: Journal of Thoracic OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Circulating tumour-macrophage fusion cells (TMFs) and in particular giant TMFs associated with unfavourable NSCLC outcomes post-surgery: https://t.co/ckgeLBWnnX #LCSM #cactc
-
-
Mashup Score: 1Deep learning of circulating tumour cells - 4 year(s) ago
Counting different types of circulating tumour cells can give valuable information on the severity of the disease and on whether treatments are effective for a specific patient. In this work, the authors show that their method based on autoencoders can identify and count cells more accurately and faster than human experts.
Source: Nature Machine IntelligenceCategories: Hem/Onc News and JournalsTweet-
Deep learning enables classification of CTCs into 5 different classes with an accuracy, sensitivity and specificity of >96%, and the obtained CTC counts predict patient OS as well as state-of-the-art manual counts: https://t.co/cbUX5AeTCX #cactc
-
Hybrid capture-based genomic profiling of ctDNA in ER+ met BrCA [8/31/17] Chung et al @Annals_Oncology https://t.co/093n8akngr #bcsm #cactc